medigraphic.com

2002, Number S1

<< Back Next >>

Arch Cardiol Mex 2002; 72 (S1)

Heparins

Martínez SCR

Language: Spanish
References: 31
Page: 135-140
PDF size: 64.50 Kb.


ABSTRACT

The use of heparins in acute coronary syndromes has been established as antithrombine indication. In acute myocardial infarction, it is considered an adjunct therapy to reperfusion strategies. In patients with angina, this antithrombine therapy experts a synergic effect with antiplatelet drugs, which also have an antithrombine effect. This pharmacological information movides the possibility to use the traditional unfractioned heparin (UFH) and low molecular heparin (LMH), both are antithrombine drugs. The advantage of these low molecular heparins is their biodisponibility and easier use. Both types of heparins are relevant since there is valid information establishing that LMH is useful in acute coronary syndromes. Such as acute myocardial infarction (AMI), yielding better results than the UFH.
Newer drugs, the pentasaccharides, have been reported recently, which. Newer drugs are small fractions of heparin, with antithrombine effects and which seem to be more powerful and effective offering better results. These drugs have been named pentasaccharides.


REFERENCES

  1. Arbustini E, Morbinini P, Dal Bello B, Patri F, Specchia G: From plaque biology to clinical setting. AM M Journal 1999; 138: 5-55. 5-60.

  2. Ajay M, Borzak S: Treatment possibilities for unstable angina. Br. Medical Journal 2000; 321: 1269-1275.

  3. White HD: Clinical trials of direct thrombin inhibitors in acute ischamic syndromes thrombosis and haemostasis, 1997; 78: 364-366.

  4. Risc group. Risk of myocardial infarction and death during treatment with lowdose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 335: 827-30.

  5. Antman EM, Cohen M, Radley R, et al: For Timi IIB-essence meta-analysis. Circulation 1999; 100: 1602-1608.

  6. Turcie A: Pentasaccharide clinical trials update. Lessions for practice. American. Heart J 2001; 142(2’s): -s9-s15.

  7. The Gusto investigators. Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries. N Engl J Med 1993; 329: 673-682.

  8. AIMS. TRIAL study groups a effect of intravenous apsal on mortality after acute myocardial infarction. Lancet 1988; 1: 545-549.

  9. Isam study group. A prospective trial of intravenous streptokinase in acute myocardial infarction. N Engl J Med 1986; 314: 1465-1471.

  10. Grupo GISSI. Gruppo italiano perlo studio della streptochinasi Nell’ infartio miocardico. Lancet 1986; 1: 397-401.

  11. ISIS–2. (Second international study of infarct survival) collaborative group. Randomised trial of intravenous streptokinase, Oral aspirin both or neither among 17,187 cases of suspected acute. Myocardial infarction. Lancet 1988; II: 349-360.

  12. GISSI-2. Factorial randomized total of alteplase vs streptokinase and heparin vs no heparin. Lancet 1990; 336: 65-71.

  13. ISIS-3. A randomizes comparison of streptokinase vs tisue plasminogen activator vs anistreplase and of aspirin plus heparini vs aspirini alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-770.

  14. Boersma E, Harrington R, Whithe H, et al: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of major randomisen clinicial trials. Lancet 2002; 359: 189-198.

  15. Herman H: Triple therapy of acute myocardial infarction: combining fibrinolysis, platelet IIb/IIIa inhibition, and percutaneus coronary intervention. Am J of Cardiol 2000; 85(8-A): 10C-16C.

  16. Gibson MC. A union in reperfussion: the concept of facilited percutaneus coronary intervention. JACC 2000; 36: 1497-99.

  17. Antman E et al: Abciximab facilitates. The rate and extient of thrombolysis (TIMI 14): Circulation 1999; 99: 2720-2732.

  18. Theroux P, Quimet H, McCons J, et al: Aspirin, heparin or both to treat unstable angina. N Engl Med 1988; 319: 1105-1111.

  19. Frisc, Group. Low molecular weight heparina during instabilityu in coronary disease. Lancet 1996; 347: 561-568.

  20. The thrombolysis in myocardial infarction (TIMI) IIA. Trial investigators. Dose-ranging trial of enoxaparin for unstable angina. Result of TIMI IIA. JACC 1997; 29: 1474-1482.

  21. Monrad ES: Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction. AM J of Cardiol 2000; 85: (8-A), 2C-9C.

  22. Antman EM. The timi risk score for unstable angina/Mon-St elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000; 284: 835-842.

  23. Antman EM, Tanasiejevic MC, Thomson B et al: Cardiac specific troponin I. Levels to predict the risk of mortality in patients with acute coronary syndromes. M Engl J Med 1996; 335: 1342-1399.

  24. Cannon CP, Weintraub WS, Demopoulos LA, et al: Comparison of early invasive and conservative strategies implement with unstable coronary syndromes treated with glycoprotein IIb –IIIa inhibitor – tirofibam. M Engl J Med 2001; 344(25): 187.

  25. ASSENT-3. Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractional heparin: The ASSENT-3 randomized trial in acute myocardial infarction. Lancet 2001; 358: 605-613.

  26. Cohen M, Demers C, Gurfinkel EP, et al: Essence study group. A comparation of low-molecular weight heparin with unfractionated heparin for unstable coronary artery de isease. N Engl J Med 1997; 337: 447-452.

  27. Keith AF: Acute syndromes presentation-clinical spectrum and management. Heart 2000; 84: 93-100.

  28. Verheugt FW: Drug treatments. Lancet 1999; 353(Suppl II). S-20 - S-24.

  29. Barrera RC, Juárez HU, Victoria LC, y col: Niveles anti-Xa en pacientes con angor inestable de alto riesgo tratados con enoxiparina. Archs Ist Nac de Cardiol 1999; 69: 9(A-34).

  30. Victoria L, Juárez HU, Rosas PM, et al: Disminución de hemorragias totales a dosis reducidas de enoxaparina para el tratamiento inicial de la angina inestable de alto riesgo (estudio ENHNFAI). Arch de Cardiol Mex 2001; 71(S3)., 13(A-49).

  31. Victoria L, Juárez HU, Rosas PM, y cols: Enoxiparina vs heparina nofraccionada para el tratamiento inicial de la angina inestable de alto riesgo e infarto al miocardio sin onda Q. Arch Inst Nac de Cardiol 1999; 69., 27(A-107).




2020     |     www.medigraphic.com